Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Molecular Partners AG
  6. Summary
    MOLN   CH0256379097

MOLECULAR PARTNERS AG

(MOLN)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Swiss Exchange
07/26/2021 07/27/2021 07/28/2021 07/29/2021 07/30/2021 Date
18.12(c) 18.18(c) 18.16(c) 18.16(c) 18.56(c) Last
24 440 69 359 20 789 22 730 54 421 Volume
-0.22% +0.33% -0.11% 0.00% +2.20% Change
More quotes
Estimated financial data (e)
Sales 2021 64,3 M 71,0 M 71,0 M
Net income 2021 -3,11 M -3,43 M -3,43 M
Net cash position 2021 129 M 142 M 142 M
P/E ratio 2021 -194x
Yield 2021 -
Sales 2022 56,6 M 62,5 M 62,5 M
Net income 2022 -15,1 M -16,7 M -16,7 M
Net cash position 2022 89,9 M 99,3 M 99,3 M
P/E ratio 2022 -44,7x
Yield 2022 -
Capitalization 599 M 661 M 661 M
EV / Sales 2021 7,32x
EV / Sales 2022 8,99x
Nbr of Employees 152
Free-Float 77,4%
More Financials
Company
Molecular Partners AG is a Switzerland-based clinical-stage biotech company developing DARPin (Designed Ankyrin Repeat Proteins) a new class of custom-built protein therapeutics based on natural binding proteins that open a new dimension of multi-functionality and multi-target specificity in drug design. The Company has formed partnerships with leading pharmaceutical companies to advance DARPin therapeutics , and... 
More about the company
Ratings of Molecular Partners AG
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C
More Ratings
All news about MOLECULAR PARTNERS AG
07/13ANALYST RECOMMENDATIONS : Allegiant Travel, Electronic Arts, Molecular Partners,..
07/13MOLECULAR PARTNERS : Cowen Starts Molecular Partners at Outperform With $50 Pric..
MT
07/08MOLECULAR PARTNERS : Says In Vitro Data Show Its COVID-19 Vaccine Candidate Main..
MT
07/08MOLECULAR PARTNERS : Reports Positive In Vitro Data On Potential COVID-19 Therap..
MT
07/08Molecular Partners Reports Continued Progress of Ensovibep Global Clinical Pr..
GL
07/08Molecular Partners Reports Continued Progress of Ensovibep Global Clinical Pr..
CI
06/21CITIGROUP : Molecular Partners Selects Citi as Depositary Bank for ADR Program
MT
06/18ANALYST RECOMMENDATIONS : American Express, HSBC, CyrusOne, Microsoft, Vodafone...
06/17MOLECULAR PARTNERS AG(NASDAQGS : MOLN) added to NASDAQ Composite Index
CI
06/16Molecular Partners Prices IPO at $21.25 Per ADS
MT
06/15MOLECULAR PARTNERS : Prices US IPO to Raise $64 Million
MT
06/15MOLECULAR PARTNERS : Announces Pricing of Initial Public Offering of American De..
PU
06/13MOLECULAR PARTNERS : Gets US FDA Fast Track Designation For Ensovibep in COVID-1..
MT
06/13MOLECULAR PARTNERS : Announces First Patient Dosed in COVID-19 NIH-Sponsored ACT..
PU
06/09MOLECULAR PARTNERS : to Launch ADSs Listing in US
MT
More news
News in other languages on MOLECULAR PARTNERS AG
07/30Principales informations en matinée
07/30Morning Briefing - Markt Schweiz
07/30ZURICH STOCK EXCHANGE : 4-Wochenvorschau Schweiz
07/20AUSBLICK NOVARTIS : Quartalsumsatz von 12,6 Milliarden US-Dollar erwartet
07/20PRÉVISIONS NOVARTIS : revenus trimestriels autour de 12,6 milliards de dollars
More news
Analyst Recommendations on MOLECULAR PARTNERS AG
More recommendations
Chart MOLECULAR PARTNERS AG
Duration : Period :
Molecular Partners AG Technical Analysis Chart | MOLN | CH0256379097 | MarketScreener
Technical analysis trends MOLECULAR PARTNERS AG
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 7
Last Close Price 18,56 CHF
Average target price 29,57 CHF
Spread / Average Target 59,3%
EPS Revisions
Managers and Directors
Patrick Amstutz Chief Executive Officer & Director
Andreas Emmenegger Chief Financial Officer
William Matt Burns Chairman
Daniel Steiner Senior Vice President-Research
Nicolas Leupin Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
MOLECULAR PARTNERS AG-10.55%661
GILEAD SCIENCES, INC.19.86%85 648
BIONTECH SE302.78%79 303
WUXI APPTEC CO., LTD.33.61%59 516
REGENERON PHARMACEUTICALS20.70%59 505
VERTEX PHARMACEUTICALS-14.71%52 296